Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Charantin** is a plant-derived steroidal glycoside preparation isolated principally from *Momordica charantia* (bitter melon). The commonly used chemical definition is a naturally occurring mixture of beta-sitosteryl glucoside and stigmasteryl glucoside. It has been investigated preclinically for metabolic effects, including antihyperglycemic and lipid-lowering activity. In a high-lipid-diet rat model, charantin reduced circulating cholesterol, triglycerides, LDL, and VLDL while increasing HDL; reported mechanistic findings included reduced HMGCR, PCSK9, and APOB expression and increased LDLR and PPAR-alpha expression. Charantin is not an established approved pharmaceutical product for hyperlipidemia or diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on charantin.